Log in

Zymeworks Stock Forecast, Price & News

+1.99 (+4.59 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $45.34
50-Day Range
MA: $32.34
52-Week Range
Now: $45.34
Volume561,175 shs
Average Volume464,262 shs
Market Capitalization$2.07 billion
P/E RatioN/A
Dividend YieldN/A
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Zymeworks logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Previous SymbolNASDAQ:ZYME



Sales & Book Value

Annual Sales$29.54 million
Book Value$6.21 per share


Net Income$-145,440,000.00
Net Margins-569.13%


Market Cap$2.07 billion
Next Earnings Date11/3/2020 (Estimated)
+1.99 (+4.59 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock been impacted by Coronavirus?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZYME stock has increased by 40.5% and is now trading at $45.34.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Zymeworks?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zymeworks

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.77) EPS for the quarter, beating the Zacks' consensus estimate of ($0.86) by $0.09. The firm earned $12.36 million during the quarter, compared to the consensus estimate of $8.54 million. Zymeworks had a negative net margin of 569.13% and a negative return on equity of 44.06%.
View Zymeworks' earnings history

What price target have analysts set for ZYME?

12 brokerages have issued 1-year price targets for Zymeworks' stock. Their forecasts range from $42.00 to $70.00. On average, they expect Zymeworks' stock price to reach $52.91 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Zymeworks

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 2,600,000 shares, an increase of 13.0% from the July 30th total of 2,300,000 shares. Based on an average trading volume of 458,300 shares, the days-to-cover ratio is presently 5.7 days. Approximately 6.7% of the company's shares are short sold.
View Zymeworks' Short Interest

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include NVIDIA (NVDA), Just Energy Group (JE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Paypal (PYPL), Cronos Group (CRON), Just Energy Group (JE), Tesla (TSLA), Alibaba Group (BABA) and Crispr Therapeutics (CRSP).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.85%), FMR LLC (7.49%), FIL Ltd (7.40%), Great Point Partners LLC (5.64%), Cormorant Asset Management LP (1.21%) and Two Sigma Advisers LP (1.17%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Diana Hausman, Eli & Co Lilly, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks

Which major investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Nuveen Asset Management LLC, Alps Advisors Inc., Picton Mahoney Asset Management, Marshall Wace North America L.P., Taylor Wealth Management Partners, UBS Group AG, and Chartwell Investment Partners LLC.
View insider buying and selling activity for Zymeworks

Which major investors are buying Zymeworks stock?

ZYME stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Great Point Partners LLC, Sofinnova Investments Inc., FIL Ltd, Candriam Luxembourg S.C.A., Barclays PLC, Swiss National Bank, and Marshall Wace LLP. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $45.34.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $2.07 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 180 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.